keyword
https://read.qxmd.com/read/38679893/effect-of-resveratrol-on-mmp-2-expression-in-scleral-fibroblasts-an-in-vitro-study
#1
JOURNAL ARTICLE
Xiaolan Tang, Sha Lv, Shichun Liu, Shengfang Song, Hua Li
PURPOSE: To investigate the effects of resveratrol (Res) on human fetal scleral fibroblasts (HFSFs) and its potential mechanism. METHODS: HFSFs were randomly divided into the Res-treated group and the control group. Following, HFSFs were treated with or without a concentration of 10 μM Res for 48 h. To detect the expression of related genes, reverse transcription quantitative PCR (RT-qPCR) and western blotting were used. The apoptosis rate of different groups was determined using flow cytometry...
April 28, 2024: Current Eye Research
https://read.qxmd.com/read/38666493/feasibility-of-direct-vitrectomy-sparing-subretinal-injection-for-gene-delivery-in-large-animals
#2
JOURNAL ARTICLE
Zbynek Stranak, Taras Ardan, Yaroslav Nemesh, Maria Toms, Lyes Toualbi, Richard Harbottle, Zdenka Ellederova, Lyubomyr Lytvynchuk, Goran Petrovski, Jan Motlik, Mariya Moosajee, Igor Kozak
PURPOSE: To assess the safety and feasibility of direct vitrectomy-sparing subretinal injection for gene delivery in a large animal model. METHODS: The experimental Liběchov minipigs were used for subretinal delivery of a plasmid DNA vector (pS/MAR-CMV-copGFP) with cytomegalovirus (CMV) promoter, green fluorescent protein (GFP) reporter (copGFP) and a scaffold/matrix attachment region (S/MAR) sequence. The eyes were randomized to subretinal injection of the vector following pars plana vitrectomy (control group) or a direct injection without prior vitrectomy surgery (experimental group)...
April 26, 2024: Current Eye Research
https://read.qxmd.com/read/38663712/gyrate-atrophy-of-the-choroid-and-retina-update-on-diagnosis-and-treatment
#3
REVIEW
M T Merino Diez, C Soria Prada, M Zamorano Aleixandre, J J Gonzalez-Lopez
Gyrate atrophy of the choroid and retina (GACR) is a rare autosomal recessive disease characterised by elevated plasma ornithine levels due to deficiency of the enzyme ornithine aminotransferase (OAT). The accumulation of this amino acid in plasma leads to the development of patches of chorioretinal atrophy in the peripheral retina extending into the macular area. Patients usually present with night blindness followed by constriction of the visual field and, finally, decreased central vision and blindness. The disease is diagnosed by the presence of the characteristic clinical picture, the presence of hyperornithinaemia in plasma and the detection of mutations in the OAT enzyme gene...
April 23, 2024: Archivos de la Sociedad Española de Oftalmología
https://read.qxmd.com/read/38654984/therapeutic-future-of-fuchs-endothelial-corneal-dystrophy-an-ongoing-way-to-explore
#4
REVIEW
Jia-Xin Liu, Tung-Lin Chiang, Kai-Feng Hung, Yi-Chen Sun
Fuchs endothelial corneal dystrophy (FECD) is one of the most common corneal diseases that causes loss of visual acuity in the world. FECD is a genetically and pathogenetically heterogeneous disease that results in the failure of corneal endothelial cells to maintain fluid balance and functional homeostasis of the cornea. Corneal edema, central guttae formation, and bullae development are common corneal pathologies. Currently, the mainstay of FECD treatment is surgery. However, limited sources of corneal graft and postsurgical complications remain problematic...
2024: Taiwan Journal of Ophthalmology
https://read.qxmd.com/read/38646925/rose-bengal-photodynamic-therapy-rb-pdt-modulates-the-inflammatory-response-in-lps-stimulated-human-corneal-fibroblasts-by-influencing-nf-%C3%AE%C2%BAb-and-p38-mapk-signaling-pathways
#5
JOURNAL ARTICLE
Ning Chai, Tanja Stachon, Tim Berger, Zhen Li, Maryam Amini, Shweta Suiwal, Berthold Seitz, Achim Langenbucher, Nóra Szentmáry
PURPOSE: To investigate the effect of rose bengal photodynamic therapy on lipopolysaccharide-induced inflammation in human corneal fibroblasts. Furthermore, to analyze potential involvement of the mitogen-activated protein kinase and nuclear factor kappa B signaling pathways in this process. METHODS: Human corneal fibroblast cultures underwent 0-2.0 µg/mL lipopolysaccharide treatment, and 24 h later rose bengal photodynamic therapy (0.001% RB, 565 nm wavelength illumination, 0...
April 22, 2024: Current Eye Research
https://read.qxmd.com/read/38636802/intraocular-mrna-delivery-with-endogenous-mmpeg10-based-virus-like-particles
#6
JOURNAL ARTICLE
Mengke Li, Zhong Liu, Dongliang Wang, Jinguo Ye, Zhuoxing Shi, Caineng Pan, Qikai Zhang, Rong Ju, Yingfeng Zheng, Yizhi Liu
Virus-like particles (VLP) are a promising tool for intracellular gene delivery, yet their potential in ocular gene therapy remains underexplored. In this study, we bridged this knowledge gap by demonstrating the successful generation and application of vesicular stomatitis virus glycoprotein (VSVG)-pseudotyped mouse PEG10 (MmPEG10)-VLP for intraocular mRNA delivery. Our findings revealed that PEG10-VLP can efficiently deliver GFP mRNA to adult retinal pigment epithelial cell line-19 (ARPE-19) cells, leading to transient expression...
April 16, 2024: Experimental Eye Research
https://read.qxmd.com/read/38627549/voretigene-neparvovec-for-inherited-retinal-dystrophy-due-to-rpe65-mutations-a-scoping-review-of-eligibility-and-treatment-challenges-from-clinical-trials-to-real-practice
#7
REVIEW
Francesco Testa, Giacomo Bacci, Benedetto Falsini, Giancarlo Iarossi, Paolo Melillo, Dario Pasquale Mucciolo, Vittoria Murro, Anna Paola Salvetti, Andrea Sodi, Giovanni Staurenghi, Francesca Simonelli
Biallelic mutations in the RPE65 gene affect nearly 8% of Leber Congenital Amaurosis and 2% of Retinitis Pigmentosa cases. Voretigene neparvovec (VN) is the first gene therapy approach approved for their treatment. To date, real life experience has demonstrated functional improvements following VN treatment, which are consistent with the clinical trials outcomes. However, there is currently no consensus on the characteristics for eligibility for VN treatment. We reviewed relevant literature to explore whether recommendations on patient eligibility can be extrapolated following VN marketing...
April 16, 2024: Eye
https://read.qxmd.com/read/38587442/longitudinal-assessment-of-oct-based-measures-of-foveal-cone-structure-in-achromatopsia
#8
JOURNAL ARTICLE
Garrett Grissim, Ashleigh Walesa, Hannah M Follett, Brian P Higgins, Kaitlin Goetschel, Heather Heitkotter, Joseph Carroll
PURPOSE: Achromatopsia (ACHM) is an autosomal recessive retinal disease associated with reduced or absent cone function. There is debate regarding the extent to which cone structure shows progressive degeneration in patients with ACHM. Here, we used optical coherence tomography (OCT) images to evaluate outer nuclear layer (ONL) thickness and ellipsoid zone (EZ) integrity over time in individuals with ACHM. METHODS: Sixty-three individuals with genetically confirmed ACHM with follow-up ranging from about 6 months to 10 years were imaged using either Bioptigen or Cirrus OCT...
April 1, 2024: Investigative Ophthalmology & Visual Science
https://read.qxmd.com/read/38558091/exploring-the-impact-of-saccharin-on-neovascular-age-related-macular-degeneration-a-comprehensive-study-in-patients-and-mice
#9
JOURNAL ARTICLE
Steffen E Künzel, Inga-Marie Pompös, Leonie T M Flesch, Dominik P Frentzel, Vitus A Knecht, Silvia Winkler, Sergej Skosyrski, Anne Rübsam, Felix Dreher, Norbert Kociok, Moritz Schütte, Alexandre Dubrac, Bodo Lange, Marie-Laure Yaspo, Hans Lehrach, Olaf Strauß, Antonia M Joussen, Oliver Zeitz
PURPOSE: We aimed to determine the impact of artificial sweeteners (AS), especially saccharin, on the progression and treatment efficacy of patients with neovascular age-related macular degeneration (nAMD) under anti-vascular endothelial growth factor (anti-VEGF-A) treatment. METHODS: In a cross-sectional study involving 46 patients with nAMD undergoing intravitreal anti-VEGF therapy, 6 AS metabolites were detected in peripheral blood using liquid chromatography - tandem mass spectrometry (LC-MS/MS)...
April 1, 2024: Investigative Ophthalmology & Visual Science
https://read.qxmd.com/read/38522724/iqcb1-nphp5-retinopathy-clinical-and-genetic-characterization-and-natural-history
#10
JOURNAL ARTICLE
Sagnik Sen, Lorenzo Fabozzi, Kaoru Fujinami, Yu Fujinami-Yokokawa, Genevieve A Wright, Andrew Webster, Omar Mahroo, Anthony G Robson, Michalis Georgiou, Michel Michaelides
PURPOSE: To describe the clinical and genetic features, and explore the natural history of retinopathy associated with IQCB1 variants in children and adults with retinopathy. DESIGN: Retrospective cohort study at a single tertiary care referral center. METHODS: The study recruited 19 patients with retinopathy, harboring likely disease-causing variants in IQCB1. Demographic data and clinical presentation, best corrected visual acuity (BCVA), fundus appearance, optical coherence tomography (OCT) and autofluorescence features, electroretinography (ERG) and molecular genetics are reported...
March 22, 2024: American Journal of Ophthalmology
https://read.qxmd.com/read/38519591/precision-ophthalmology-a-call-for-africa-not-to-be-left-in-the-dark
#11
REVIEW
Lisa Roberts
No abstract text is available yet for this article.
March 22, 2024: Gene Therapy
https://read.qxmd.com/read/38512246/clinical-features-and-treatment-outcomes-of-carbapenem-resistant-pseudomonas-aeruginosa-keratitis
#12
JOURNAL ARTICLE
Felipe Echeverri Tribin, Caroline Lieux, Jorge Maestre-Mesa, Heather Durkee, Katherine Krishna, Brandon Chou, Emily Neag, Jana D'Amato Tóthová, Jaime D Martinez, Harry W Flynn, Jean Marie Parel, Darlene Miller, Guillermo Amescua
IMPORTANCE: Evaluation of the microbiological diagnostic profile of multidrug-resistant Pseudomonas aeruginosa keratitis and potential management with rose bengal-photodynamic antimicrobial therapy (RB-PDAT) is important. OBJECTIVE: To document the disease progression of carbapenemase-resistant P aeruginosa keratitis after an artificial tear contamination outbreak. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observation case series included 9 patients 40 years or older who presented at Bascom Palmer Eye Institute and had positive test results for multidrug-resistant P aeruginosa keratitis between January 1, 2022, and October 31, 2023...
March 21, 2024: JAMA Ophthalmology
https://read.qxmd.com/read/38508214/rpe65-associated-retinal-dystrophies-phenotypes-and-treatment-effects-with-voretigene-neparvovec
#13
REVIEW
Katarina Stingl, Claudia Priglinger, Philipp Herrmann
Retinal dystrophies linked to the RPE65 gene are mostly fast-progressing retinal diseases, with childhood onset of night blindness and progressive visual loss up to the middle adult age. Rare phenotypes linked to this gene are known with congenital stationary night blindness or slowly progressing retinitis pigmentosa, as well as an autosomal dominant c.1430A>G (p.Asp477Gly) variant. This review gives an overview of the current knowledge of the clinical phenotypes, as well as experience with the efficacy and safety of the approved gene augmentation therapy voretigene neparvovec...
March 2024: Klinische Monatsblätter Für Augenheilkunde
https://read.qxmd.com/read/38508213/-rpe65-retinal-dystrophies-from-the-spectrum-of-the-clinical-picture-to-gene-therapy
#14
JOURNAL ARTICLE
Katarina Stingl, Claudia Priglinger
No abstract text is available yet for this article.
March 2024: Klinische Monatsblätter Für Augenheilkunde
https://read.qxmd.com/read/38500388/inherited-retinal-dystrophies-and-orphan-designations-in-the-european-union
#15
REVIEW
Jane Moseley, Tim Leest, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska
Inherited Retinal Dystrophies (IRD) are diverse rare diseases that affect the retina and lead to visual impairment or blindness. Research in this field is ongoing, with over 60 EU orphan medicinal products designated in this therapeutic area by the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA). Up to now, COMP has used traditional disease terms, like retinitis pigmentosa, for orphan designation regardless of the product's mechanism of action. The COMP reviewed the designation approach for IRDs taking into account all previous Orphan Designations (OD) experience in IRDs, the most relevant up to date scientific literature and input from patients and clinical experts...
March 18, 2024: European Journal of Ophthalmology
https://read.qxmd.com/read/38499336/disease-specific-variant-interpretation-highlighted-the-genetic-findings-in-2325-japanese-patients-with-retinitis-pigmentosa-and-allied-diseases
#16
JOURNAL ARTICLE
Kensuke Goto, Yoshito Koyanagi, Masato Akiyama, Yusuke Murakami, Masatoshi Fukushima, Kohta Fujiwara, Hanae Iijima, Mitsuyo Yamaguchi, Mikiko Endo, Kazuki Hashimoto, Masataka Ishizu, Toshiaki Hirakata, Kei Mizobuchi, Masakazu Takayama, Junya Ota, Ai Fujita Sajiki, Taro Kominami, Hiroaki Ushida, Kosuke Fujita, Hiroki Kaneko, Shinji Ueno, Takaaki Hayashi, Chikashi Terao, Yoshihiro Hotta, Akira Murakami, Kazuki Kuniyoshi, Shunji Kusaka, Yuko Wada, Toshiaki Abe, Toru Nakazawa, Yasuhiro Ikeda, Yukihide Momozawa, Koh-Hei Sonoda, Koji M Nishiguchi
BACKGROUND: As gene-specific therapy for inherited retinal dystrophy (IRD) advances, unified variant interpretation across institutes is becoming increasingly important. This study aims to update the genetic findings of 86 retinitis pigmentosa (RP)-related genes in a large number of Japanese patients with RP by applying the standardised variant interpretation guidelines for Japanese patients with IRD (J-IRD-VI guidelines) built upon the American College of Medical Genetics and Genomics and the Association for Molecular Pathology rules, and assess the contribution of these genes in RP-allied diseases...
March 18, 2024: Journal of Medical Genetics
https://read.qxmd.com/read/38485090/frequency-and-distribution-of-ophthalmic-surgical-procedures-among-patients-with-inherited-retinal-diseases
#17
JOURNAL ARTICLE
Lukas Mees, Mingyi Li, Bani Antonio-Aguirre, T Y Alvin Liu, Adela Wu, Xiangrong Kong, Mandeep S Singh
OBJECTIVE OR PURPOSE: In this study, we aimed to characterize the frequency and distribution of ocular surgeries in patients with inherited retinal diseases (IRDs) and evaluate associated patient and disease factors. DESIGN: Retrospective cohort. PARTICIPANTS: Subjects 18 years and older who were followed at the Johns Hopkins Genetic Eye Disease (GEDi) Center. METHODS: We studied a retrospective cohort of patients with an IRD diagnosis to analyze the occurrence of laser and incisional surgeries...
March 12, 2024: Ophthalmology Retina
https://read.qxmd.com/read/38467992/cystoid-macular-oedema-in-a-patient-treated-with-sting-agonist-and-ezabenlimab-for-disseminated-melanoma
#18
JOURNAL ARTICLE
Peter Kiraly, M Dominik Fischer
INTRODUCTION: We describe a case of cystoid macular oedema associated with combination treatment using a STING agonist and ezabenlimab for disseminated melanoma. CASE REPORT: A 66-year-old male patient presented with worsening vision and cystoid macular oedema in the right eye, along with a small accumulation of subretinal fluid in the left eye. The patient has been undergoing treatment for melanoma since 2014. Five months prior to the ocular presentation, the patient was enrolled in a first-in-human trial with a STING agonist and ezabenlimab...
March 11, 2024: Ophthalmology and Therapy
https://read.qxmd.com/read/38466290/genotype-phenotype-of-crb1-associated-early-onset-retinal-dystrophy-novel-insights-on-retinal-architecture-and-therapeutic-window-for-clinical-trials
#19
JOURNAL ARTICLE
Yili Jin, Songshan Li, Zhaoxin Jiang, Limei Sun, Li Huang, Ting Zhang, Xinyu Liu, Xiaoyan Ding
PURPOSE: The purpose of this study was to investigate the genotypic and phenotypic characteristics of CRB1-associated early onset retinal dystrophy (CRB1-eoRD) and retinal architecture by swept-source optical coherence tomography (SS-OCT). METHODS: Eleven probands with CRB1-eoRD were recruited. Clinical information, genetic analysis, and comprehensive ophthalmic examinations including SS-OCT and SS-OCT angiography (SS-OCTA) were conducted. RESULTS: A total of 81...
March 5, 2024: Investigative Ophthalmology & Visual Science
https://read.qxmd.com/read/38462459/viral-vectors-in-gene-replacement-therapy
#20
REVIEW
Ekaterina Minskaia, Alima Galieva, Alexander D Egorov, Roman Ivanov, Alexander Karabelsky
Throughout the years, several hundred million people with rare genetic disorders have been receiving only symptom management therapy. However, research and development efforts worldwide have led to the development of long-lasting, highly efficient, and safe gene therapy for a wide range of hereditary diseases. Improved viral vectors are now able to evade the preexisting immunity and more efficiently target and transduce therapeutically relevant cells, ensuring genome maintenance and expression of transgenes at the relevant levels...
December 2023: Biochemistry. Biokhimii︠a︡
keyword
keyword
70733
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.